• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by NuVasive Inc.

    1/26/22 11:54:33 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care
    Get the next $NUVA alert in real time by email
    SC 13G 1 NUVASIVE_INC.htm FILING NUVASIVE, INC. Schedule 13G


     
    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. )*
     
    NUVASIVE, INC. 

    (Name of Issuer)
     
    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     
    670704105

    (CUSIP Number)
     
    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         x  Rule 13d-1(b)
     
         o  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  670704105            
     
               
    1   NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
      JPMORGAN CHASE & CO.

    13-2624428
         
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)



      (a)   o
      (b)   o
         
    3   SEC USE ONLY
       
       
         
    4   CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware
           
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:  5   SOLE VOTING POWER
       
      2,496,946
         
    6   SHARED VOTING POWER
       
      0
         
    7   SOLE DISPOSITIVE POWER
       
      2,898,128
         
    8   SHARED DISPOSITIVE POWER
       
      5
         
    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      2,911,233
         
    10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      o
         
    11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      5.6 %
         
    12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      HC
     

    FOOTNOTES
       
     
     
     

     
     
    Item 1.


     
    (a)
    Name of Issuer
     
     
    NUVASIVE, INC.


     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    7475 Lusk Boulevard
    San Diego, CA 92121


    Item 2.


     
    (a)
    Name of Person Filing
     
     
    JPMORGAN CHASE & CO.


     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    383 Madison Avenue
    New York, NY 10179


     
    (c)
    Citizenship
     
     
    Delaware


     
    (d)
    Title of Class of Securities
     
     
    Common Stock, par value $0.001 per share


     
    (e)
    CUSIP Number
     
     
    670704105


     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:


     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).


     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).


     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).


     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).


     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);


     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);


     
    (g)
    x
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);


     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).


     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.


     
    (a)
    Amount beneficially owned: 2,911,233


     
    (b)
    Percent of class: 5.6 %


     
    (c)
    Number of shares as to which the person has:


     
    (i)
    Sole power to vote or to direct the vote: 2,496,946


     
    (ii)
    Shared power to vote or to direct the vote: 0


     
    (iii)
    Sole power to dispose or to direct the disposition of: 2,898,128


     
    (iv)
    Shared power to dispose or to direct the disposition of: 5


    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .
     
     
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    Not Applicable
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    J.P. Morgan Trust Company of Delaware
    J.P. Morgan Securities LLC
    JPMorgan Asset Management (UK) Limited
    JPMorgan Chase Bank, National Association
    J.P. Morgan Investment Management Inc.
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Not Applicable
     
    Item 9.
    Notice of Dissolution of Group
     
    Not Applicable
     
     
     

     
     
     
    Item 10.
    Certification
       
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     


    SIGNATURE


    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
      JPMORGAN CHASE & CO.

     
           
    Date: January 26, 2022
    By:
    /s/  Rachel Tsvaygoft  
        Name: Rachel Tsvaygoft  
        Title:  Vice President  
           
     
    Footnotes:


    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     



    Get the next $NUVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUVA

    DatePrice TargetRatingAnalyst
    2/10/2023$57.72Overweight → Equal Weight
    Wells Fargo
    2/10/2023$63.00 → $52.00Buy → Neutral
    Citigroup
    2/10/2023$51.00 → $52.50Buy → Hold
    Truist
    1/6/2023Buy → Hold
    Needham
    10/18/2022$53.00Overweight
    Barclays
    10/12/2022$45.00Hold
    Jefferies
    4/13/2022$60.00 → $65.00Buy
    Truist
    3/28/2022$58.00Overweight
    Wells Fargo
    More analyst ratings

    $NUVA
    SEC Filings

    See more
    • SEC Form 15-12G filed by NuVasive Inc.

      15-12G - NUVASIVE INC (0001142596) (Filer)

      9/11/23 4:46:57 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by NuVasive Inc.

      EFFECT - NUVASIVE INC (0001142596) (Filer)

      9/8/23 12:15:09 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by NuVasive Inc.

      EFFECT - NUVASIVE INC (0001142596) (Filer)

      9/8/23 12:15:14 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by NuVasive Inc. (Amendment)

      SC 13G/A - NUVASIVE INC (0001142596) (Subject)

      9/11/23 1:33:44 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by NuVasive Inc.

      SC 13G - NUVASIVE INC (0001142596) (Subject)

      2/13/23 3:58:05 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by NuVasive Inc. (Amendment)

      SC 13G/A - NUVASIVE INC (0001142596) (Subject)

      12/6/22 10:35:04 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    Financials

    Live finance-specific insights

    See more
    • NuVasive Announces Second Quarter 2023 Financial Results

      –U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi

      8/2/23 4:05:00 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • NuVasive Announces Conference Call and Webcast of Second Quarter 2023 Results

      SAN DIEGO, July 24, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that it will release its second quarter 2023 results on Wednesday, August 2, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, August 2, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the second quarter of 2023. The dial-in numbers are 1-877-407-9039 for domestic calle

      7/24/23 7:00:00 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • NuVasive Announces First Quarter 2023 Financial Results

      –Continued above-market worldwide net sales growth of 5.8% as reported and 7.7% on a constant currency basis––U.S. cervical delivers sixth consecutive quarter of greater than 20% growth, driven by C360 and the Simplify Cervical Disc– SAN DIEGO, May 10, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2023. First Quarter 2023 Highlights Net sales were $307.7 million, a

      5/10/23 4:05:00 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    Leadership Updates

    Live Leadership Updates

    See more
    • BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council

      SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

      9/7/22 8:30:00 AM ET
      $AFIB
      $AVGR
      $HYPR
      $NUVA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • Blue Spark Technologies Announces Appointment of John DeFord, Ph.D. to its Board of Directors

      The new board member will provide extensive expertise to expand the TempTraq® remote patient monitoring platform Blue Spark Technologies Inc., a leader in wearable remote patient monitoring solutions, announced today the appointment of John DeFord, Ph.D. to its board of directors. Dr. DeFord's appointment, effective April 13th, 2022, brings the number of board members to five. "This is really an inflection point for the company and it's an exciting time to be involved. I look forward to helping mold the future of their technology," said Dr. DeFord. "I'm particularly excited to see the technology come together that will make an impact in patient's lives." "We are proud to welcome John to

      5/2/22 7:00:00 AM ET
      $NDSN
      $NUVA
      Industrial Machinery/Components
      Industrials
      Medical/Dental Instruments
      Health Care
    • NuVasive Appoints Andrew C. Morton as Chief Human Resources Officer

      SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment of Andrew (Drew) C. Morton as senior vice president and chief human resources officer (CHRO) effective February 7, 2022. Mr. Morton brings more than 25 years of experience in human resources, talent development, employee experience, and diversity and inclusion. As CHRO, Mr. Morton will oversee all human resources aspects of the Company

      1/31/22 4:10:00 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NuVasive downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded NuVasive from Overweight to Equal Weight and set a new price target of $57.72

      2/10/23 8:01:18 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • NuVasive downgraded by Citigroup with a new price target

      Citigroup downgraded NuVasive from Buy to Neutral and set a new price target of $52.00 from $63.00 previously

      2/10/23 7:45:41 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • NuVasive downgraded by Truist with a new price target

      Truist downgraded NuVasive from Buy to Hold and set a new price target of $52.50 from $51.00 previously

      2/10/23 7:45:03 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NuVasive to Participate as Double Diamond Sponsor at Scoliosis Research Society Annual Meeting

      SAN DIEGO, Aug. 30, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Scoliosis Research Society (SRS) as a double diamond sponsor and will attend the 58th Annual Meeting held September 6-9, 2023, in Seattle.  "We partner with esteemed societies like SRS because of our shared dedication to clinical research, education, and thought leadership around advancing patient care, especi

      8/30/23 7:00:00 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • Goosehead Insurance and Jackson Financial Set to Join S&P SmallCap 600

      NEW YORK, Aug. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 1: Goosehead Insurance Inc. (NASD: GSHD) will replace NuVasive Inc. (NASD: NUVA) in the S&P SmallCap 600. S&P MidCap 400 constituent Globus Medical Inc. (NYSE:GMED) is acquiring NuVasive in a deal expected to close soon pending final conditions.Jackson Financial Inc. (NYSE:JXN) will replace NexTier Oilfield Solutions Inc. (NYSE:NEX) in the S&P SmallCap 600. S&P SmallCap 600 constituent Patterson-UTI Energy Inc. (NASD: PTEN) is acquiring NexTier Oilfield Solutions in a deal expected to close soon pending final cond

      8/28/23 5:41:00 PM ET
      $GMED
      $GSHD
      $JXN
      $NEX
      Medical/Dental Instruments
      Health Care
      Specialty Insurers
      Finance
    • NuVasive Announces Second Quarter 2023 Financial Results

      –U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi

      8/2/23 4:05:00 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Wolterman Dan

      4 - NUVASIVE INC (0001142596) (Issuer)

      9/5/23 5:06:55 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Raimundo Amy Belt

      4 - NUVASIVE INC (0001142596) (Issuer)

      9/5/23 5:04:52 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Norwalk Leslie V returned 3,095 shares to the company, closing all direct ownership in the company

      4 - NUVASIVE INC (0001142596) (Issuer)

      9/5/23 4:55:04 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care